Abstract Purpose: We aimed to determine the clinical role of the p53 family members p53 and p73 in the responsiveness to platinum-based chemotherapy and survival in ovarian cancer, considering their cross-talk and the p53 polymorphism at codon 72. Experimental Design: A detailed analysis of p53 and p73 in a series of122 ovarian cancers was done.We used a functional yeast-based assay to determine the p53 mutational status. Red yeast colonies, indicating mutant p53, were subsequently sequenced to determine the specific p53 alteration. p53 mutations were divided into two groups according to their previous characterization in the literature: those that efficiently inhibit transcriptionally activeTAp73 function and those that do not. A p53 polymorphism at codon 72 was determined in corresponding normal tissue or blood of ovarian cancer patients. Isoform-specific p73 expression analysis using real-time reverse transcription-PCR has previously been done in the majority of ovarian cancers included in this study. In a retrospective chart review, responsiveness to chemotherapy was assessed, and survival data with long follow-up times were collected. Results: Eighty of 122 (65.6%) of ovarian cancers harbored p53 mutations. p53 mutational status was an important determinant of responsiveness to platinum-based chemotherapy in all patients with a residual tumor of <2 cm in diameter after initial surgery (wild-type versus mutant, P = 0.029). In addition, p53 mutational status was a strong prognosticator for recurrence-free and overall survival (P < 0.0001and P = 0.003, respectively) in univariate analyses. High expression levels of dominant-negative p73 isoforms (DNp73 and DNVp73) significantly correlated with chemotherapeutic failure (P = 0.048) and with worse recurrence-free and overall survival in patients with p53 mutant cancers (P = 0.048 and P = 0.005, respectively). Eight p53 mutations, present in 19 cases, were found that efficiently inhibit TAp73 (i.e., 175H, 220C, 245S, 245D, 248W, 248Q, 266E, and 273H). Patients with p53 mutations that efficiently inhibit TAp73 function had a significantly shorter overall survival than patients with p53 mutations of unknown effect on TAp73 (P = 0.044). The p53 polymorphism at codon 72 had no influence on responsiveness to chemotherapy or survival. Conclusion: We provide the first clinical evidence that dominant-negative p73 isoforms contribute to drug resistance in vivo, underscoring the importance of a p53-p73 cross-talk. NH 2 -terminally truncated p73 isoforms were of significant clinical effect by providing an additional unfavorable factor for response to platinum-based chemotherapy and survival in p53 mutant ovarian cancers.
responsiveness to subsequent chemotherapy. Standard first-line chemotherapy consists currently of a platinum/taxane combination in ovarian cancer. Although initial response rates are high (70-80%), a significant rate of de novo resistance poses a severe limitation to treatment and a high proportion of patients will relapse with drug-resistant disease (1) . Clinical studies have shown that up to 75% of initial responders relapse by a median of 18 to 28 months (2) .
There is increasing recognition that intact p53 family signaling is crucial for the cellular response to chemotherapeutic agents. p53 is implicated in mediating cytotoxicity of anticancer agents (3) . Two recent studies showed that the p53 family member p73 also functions in the transduction of drug-induced DNA damage to the apoptotic machinery of the cell. Bergamaschi et al. and Irwin et al. showed that transcriptionally active TAp73 is induced by a wide range of clinically used agents, such as cisplatin, anthracyclines, camptothecin, taxanes, and gemcitabine (4, 5) . Irwin et al. showed that specific small interfering RNA -dependent down-regulation of TAp73 results in a decrease in drug-induced apoptosis (5) . Moreover, in vitro experiments showed that the interaction between p53 family members is important in modulating cytotoxicity of anticancer agents. NH 2 -terminally truncated isoforms of p73 (DNp73 and DNVp73), which have been found to be overexpressed in many cancers (6, 7) , act as dominant-negative inhibitors of TAp73 and wild-type p53 and are capable of inhibiting drug-induced apoptosis (4, 7) . Furthermore, certain human tumor-derived p53 mutants are able to bind and inhibit TAp73 function (4, 8 -11) . It has been shown that these p53 mutants, at least partly, confer cellular resistance through abrogation of TAp73 function (5) . A single nucleotide polymorphism at codon 72 of p53 has been found to influence the property of p53 mutants in neutralizing p73. p53 mutants harboring an arginine at codon 72 (72R) are able to more efficiently associate with TAp73 and inhibit TAp73-dependent, drug-induced apoptosis compared with p53 mutants with a proline at codon 72 (72P; ref. 4) .
Because in vitro data argue for a central role of the p53-p73 interaction in mediating cytotoxicity to anticancer agents, analysis of their clinical significance as a putative biomarker becomes important. To address this, detailed studies correlating clinical responsiveness with p53 status and p73 expression are highly warranted. We therefore determined the p53 mutational status in a series of 122 ovarian cancers and grouped the distinct p53 mutations according to their ability to inhibit TAp73 function. We also determined the p53 polymorphism at codon 72 for these cases. Corresponding isoform-specific p73 expression analysis, discriminating between TAp73 and the dominant-negative p73 isoforms, were done by real-time reverse transcription-PCR and have previously been reported for the majority of cancers included in this study (6) . Data were correlated with updated clinical data on chemoresponsiveness and survival. Patients with p53 mutations that efficiently inhibit transcriptionally active TAp73 function had a significantly shorter overall survival than patients with non-TAp73-inhibiting p53 mutations. Moreover, high expression levels of dominant-negative p73 isoforms significantly correlated with failure to respond to platinum-based chemotherapy, worse recurrence-free and overall survival in patients with p53 mutant cancers.
Materials and Methods
Tissue. Ovarian cancer tissues from 122 patients were collected during surgery at the Departments of Obstetrics and Gynecology of the Innsbruck Medical University, Austria and the Medical University of Vienna, Austria in compliance with and approved by the Institutional Review Board. Tissues were immediately snap-frozen in liquid nitrogen, pulverized in the frozen state, and stored at À80jC until used. Ninetyfour of the ovarian cancer tissues used in this study were identical to the cohort analyzed in our previous study (6) .
Corresponding normal tissues or blood of the cancer patients were available in 112 of 122 cases. These normal tissues were collected during the same or a subsequent surgical procedure, and tissues were embedded in paraffin. The origin of normal tissues used in this study is given in Table 1 .
DNA extraction from corresponding normal tissues or blood. Two 30-Am paraffin sections of each normal tissue were deparaffinized twice with 1 mL xylene and thrice with 1 mL ethanol. After drying the samples in vacuum, 200 AL of PCR buffer [HT Biotechnology Ltd., Cambridge, England: 10 mmol/L Tris-HCl (pH 9), 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , 1% Triton X-100, 0.01% (w/v) stabilizer] containing 10 mg of glass beads (GG-500-200 Glycerol Glass Controlled Pore, 120-200 mesh, Sigma Chemical Co., St. Louis, MO) and proteinase K at a final concentration of 0.6 mg/mL was added. The samples were sonicated (Branson, Canbury, CT) at 55jC for 30 minutes. Then the samples were boiled for 10 minutes and spun at 10,000 Â g for 10 minutes, and the supernatant containing the DNA was collected (12) . DNA extraction from blood leukocytes was done according to the salting out procedure by Miller et al. (13) using a DNA EXTRACTION SYSTEM II kit purchased from Vienna Lab (Vienna, Austria).
PCR from matched normal tissues. Primers p53Co72-SE (5V-CAGGTCCAGATGAAGCTC-3V) and p53Co72-AS (5V-biotin-GGGACA-GAAGATGACAGGG-3V; Genbank accession no. K03199), were used to amplify a 120-bp fragment of genomic p53 DNA. The antisense primer was biotinylated. PCR was carried out in a volume of 25 AL, including 25 ng template, 5 pmol each of sense and antisense primers, and a puReTaq Ready-To-Go PCR Bead (Amersham Biosciences, Buckinghamshire, United Kingdom), which contains 2.5 units of puReTaq DNA polymerase; 10 mmol/l Tris-HCl (pH 9.0 at room temperature); 50 mmol/L KCl; 1.5 mmol/L MgCl 2 ; 200 Amol/L dATP, dCTP, dGTP, and dTTP; and stabilizers, including bovine serum albumin. The reaction was done on a Perkin-Elmer (Norwalk, CT) GeneAmp PCR system 9700 with 40 cycles at 94jC for 30 seconds, 55jC for 30 seconds, and 72jC for 30 seconds. The reaction was preceded by a primary denaturation step at 94jC for 1 minute.
Detection of polymorphisms by pyrosequencing in matched normal tissues. Polymorphism at codon 72 of p53 was detected using 20 AL PCR products and the PSQ 96 Single Nucleotide Polymorphism Reagent kit and analyzed on a Pyrosequencer PSQ 96 (Uppsala, Sweden) according to the manufacturer's instructions (14) . Twenty-five picomoles of the sequencing primer p53Co72-SEQ (5V -GAGGCTG-CTCCCC-3V) were used to detect the polymorphism. RNA isolation and cDNA preparation from frozen ovarian cancer tissue. RNA isolation and cDNA preparation have been described in our previous study (6) .
Yeast-based functional assay for p53 and sequence analysis. To detect inactivating p53 mutations in the ovarian cancer tissues, the functional yeast-based assay was used as described previously (15, 16) . Briefly, functional yeast-based assay is based on transcriptional activity of wild-type versus mutant p53 alleles in a yeast reporter system. p53 mRNA was reverse transcribed, amplified by PCR, and cotransformed into Saccharomyces cerevisiae with a linearized yeast homologous recombination expression vector carrying the 5V and 3V ends of the p53 open reading frame. Wild-type p53, which activates transcription of the yeast ADE2 gene that encodes the phosphoribosyl-aminoimidazole carboxylase, results in white colonies, whereas mutant alleles lack transcriptional activity and result in smaller, red colonies. DNA from at least two red colonies was sequenced to characterize the p53 mutations.
Statistical analysis. Fisher's exact test or m 2 test was used to examine the relationships of clinical data, p53 mutational status, and p73 isoform expression with responsiveness to chemotherapy. (Fisher's exact test was used when the number of cases in subgroup analyses was <30 in each group. This was the case in all analyses on dominantnegative p73 isoforms and chemoresponsiveness, as well as for all analyses on p53 in different groups of residual tumor and chemoresponsiveness). As previously reported, distribution of p73 isoform expression levels in the cohort was non-Gaussian (6). The dominantnegative p73 isoforms, DNp73 and DNVp73, produce the same polypeptide; therefore, values were pooled, and cancers were divided by the median cancer level into two approximately same-sized groups [i.e., a high expressing group (above the 50th percentile) and a low expressing group (below the 50th percentile) of DNp73 and DNVp73 expression]. For correlations with patients' age, a young age group and an old age group were defined above or below the median age of all patients.
Survival probabilities were calculated by the product limit method of Kaplan and Meier. Differences between groups were tested using the log-rank test. The results were analyzed for the end points of recurrencefree and overall survival. Recurrence-free survival was calculated from the day of diagnosis until the date when progressive disease, relapse, or death was reported, whichever occurred first. Patients who had not experienced any unfavorable event were censored at the last date they were known to have been alive. Overall survival was defined as the time between diagnosis and death. Patients who had not died were censored at the last date they were known to have been alive. The Cox proportional hazard model was used for multivariate analysis to assess the independence of different prognostic factors.
Although several subgroup analyses regarding the clinical effect of the examined p53 family members were done, no corrections for multiple comparisons were applied due to the explorative character of these analyses. Ps < 0.05 were considered statistically significant.
Clinical data. In this continuative study, 77% (94 of 122) cases of ovarian cancer patients are identical to the patients analyzed in our previous study (6) . For the present study, clinical data of these 94 patients were completed, their survival was updated, and an additional 28 new ovarian cancer patients were recruited. In addition, the patients' responsiveness to chemotherapy was assessed in a retrospective chart review.
Patients were treated at the Department of Obstetrics and Gynecology, Innsbruck Medical University, Austria, between May 1990 and June 2001 and at the Department of Obstetrics and Gynecology, Medical University of Vienna, Austria, between February 1997 and November 1998. All but one patient underwent surgery; this patient received carboplatin chemotherapy alone due to impaired general health. Surgical treatment included total hysterectomy and bilateral salpingooophorectomy in all but three patients; 101 of 121 patients underwent additional omentectomy, and partial bowel resection was necessary in 17 patients. Lymph node evaluation involved pelvic lymphadenectomy in 52 of 121 patients.
The median age at the time of diagnosis was 61 years (range, 24-88 years). Patients presented with International Federation of Gynecologists and Obstetricians (FIGO) stage I (n = 30), stage II (n = 7), stage III (n = 67), and stage IV (n = 16) at the time of diagnosis. In two cases, the FIGO stage was unknown. To classify tumor grade, the widely used system based on architectural and nuclear grade and mitotic activity was applied. Ovarian cancers consisted of well (n = 8), moderately (n = 61), and poorly differentiated tumors (n = 46), whereas in seven cases the tumor grade was not available. The histopathology of tumors included adenocarcinomas of the serous (n = 45), mucinous (n = 46), endometrioid (n = 23), and clear cell subtype (n = 4) and four undifferentiated carcinomas. Distant metastases were seen in 17 patients at the time of diagnosis [lung (n = 2), pleura (n = 6), liver (n = 5), skin (n = 1), others (n = 6)]. With the exception of 11 patients with stage I carcinoma, all patients received a platinum-based chemotherapy. This involved four to six courses of carboplatin monotherapy (n = 23) or a combination therapy of cisplatin and cyclophosphamide (n = 38); cisplatin, carboplatin, and cyclophosphamide (n = 8); carboplatin and paclitaxel (n = 41); and cisplatin, paclitaxel, and cyclophosphamide (n = 2). During follow-up, 65 of 119 patients suffered recurrent ovarian cancer (three patients could not be followed for recurrence but were known to be alive), and 60 of 122 patients died. The median time of follow-up was 55 months (range, 3-235 months); the mean time of follow-up was 62 F 46 months. Data on responsiveness to chemotherapy were available in 104 of 122 patients (11 patients with FIGO stage I disease did not receive chemotherapy; in seven patients, responsiveness to chemotherapy could not be clearly determined in the chart review). Chemotherapeutic failure occurred in 34 of 104 patients.
Results
p53 mutational status in ovarian cancers. Using the highly sensitive functional yeast-based assay, 65.6% (80 of 122) of ovarian cancers were found to harbor p53 mutations, whereas 34.4% (42 of 122) were wild-type p53. In one case, two different p53 mutations were detected. The distribution of p53 missense mutations is illustrated in Fig. 1 . Table 2 lists the individual p53 alterations.
Among p53 alterations, 80.2% (65 of 81) were missense mutations, 6.2% (5 of 81) were nonsense mutations resulting in an early stop codon, and 11.1% (9 of 81) were frameshift Research.
on April 13, 2017. © 2005 American Association for Cancer clincancerres.aacrjournals.org Downloaded from mutations (six insertions and three deletions). In one case, a known polymorphism without amino acid change was detected at codon 213 (17) , and this case was included in the wild-type group. In only one case, the p53 mutation that was found in the yeast-based assay could not be identified by subsequent sequencing.
p53 mutations were scattered between exons 4 and 9 with 92.6% (75 of 81) of mutations lying within exons 5 to 8 (codons 130-286). The highest mutational rates were found in exons 7, 6, and 5 with 29.6%, 25.9%, and 22.2%, respectively. p53 missense mutations occurred in 34 different codons, spanning a total of 214 codons; 23 of 65 (35.4%) of mutations clustered in five codons: six in codon 220, five in codon 273, and four cases each in codons 195, 234, and 237.
In the examined ovarian cancers, nucleotide transitions (48 of 71, 67.6%) were found more frequently than transversions (23 of 71, 32.4%). The most common nucleotide changes were G-to-A transitions in 21 of 71 (29.6%) and A-to-G transitions in 13 of 71 (18.3%) cases; 34 of 65 (52.3%) of the observed missense mutations occurred in highly conserved regions of the p53 gene (areas II-V); 17 of 65 (26.2%) were located in the loop 3, 5 of 65 (7.8%) in loop 2, one mutation in loop 1, and one mutation in the loop-sheet-helix motif. Nine patients showed p53 mutations in three of the seven codons that are important for DNA binding (one in codon 241, three in codon 248, and five in codon 273). In three cases, p53 mutations occurred in one of the four amino acids that directly bind the zinc atom (one case in codon 176 and two cases in codon 238).
Grouping of p53 mutations based on their ability to inhibit TAp73. For further clinical correlations, we aimed to not solely consider p53 mutational status (wild type versus mutant) but also to take the interaction between mutant p53 and TAp73 into account. Thus, we grouped the observed p53 mutations according to known functional p73 interactions reported in the literature into p53 mutations that efficiently inhibit transcriptionally active TAp73 function and those with unknown effect on TAp73.
To the best of our knowledge, a total of 80 different p53 mutations have thus far been analyzed and reported for their ability to functionally interfere with p73 (4, 8 -11) . In our cohort of ovarian cancers, we found eight p53 mutations leading to altered p53 proteins that have been well characterized by several laboratories to strongly bind to p73 protein and efficiently inhibit its transactivation function in vitro. These comprise the p53 mutants 175H, 220C, 245S, 245D, 248W, 
In ovarian cancer, progressive disease during first-line chemotherapy and early recurrence within 6 months after termination of chemotherapy are defined as failure to respond to platinum-based chemotherapy. These patients are referred to have platinum-refractory and platinum-resistant disease, respectively (18 . This clearly shows that failure to chemotherapy is mainly a problem of advanced ovarian cancer (FIGO stages and responsiveness to chemotherapy: m 2 = 13.7, P = 0.008; Table 3 ). The predominant factor determining responsiveness to chemotherapy was residual disease after initial surgery ( Fig. 2A) . Among patients with complete macroscopic removal of tumor mass, only 6.5% (2 of 31) showed chemotherapeutic failure (of note, this group includes 14 cases of FIGO stage I). In patients with surgical debulking to a residual tumor of <2 cm in diameter, chemotherapeutic failure occurred in 23.3% (7 of 30) cases. Patients who were left with a residual tumor of z2 cm in diameter showed chemotherapeutic failure in 63.6% (21 of 33) cases. This difference was statistically highly significant (m 2 = 25.5, P < 0.001). The relationship between other clinicopathologic variables and responsiveness to chemotherapy are given in Table 3 .
Of interest, among all patients with surgical debulking to a residual tumor of <2 cm in diameter (excluding cases of residual tumor 0), p53 mutational status was a significant determinant of chemoresponsiveness (Fisher's exact test, P = 0.029; Fig. 2B ; Table 3 ). Although none of the 11 patients with p53 wild-type cancers in this group failed to respond to chemotherapy, 36.8% (7 of 19) patients with p53 mutant cancers showed chemotherapeutic failure. For all patients with residual tumor 0 (of note, 14 cases of FIGO stage I are included in this group) or residual tumor z2 cm in diameter, p53 mutational status had no significant influence on responsiveness to chemotherapy (Fisher's exact test, P = 1 and P = 0.223, respectively; Table 3 ). An interesting additional finding was that the highest rate of p53 mutations was seen in patients with a residual tumor of z2 cm (75.7%, 28 of 37) followed by 63.3% (19 of 30) in patients with a residual tumor <2 cm and 55.6% (25 of 45) in patients with residual tumor 0.
High levels of dominant-negative p73 isoforms in p53 mutant cancers correlate with chemotherapeutic failure in vivo. Furthermore, overexpression of dominant-negative p73 isoforms (DNp73 and DNVp73) was significantly correlated with responsiveness to chemotherapy in p53 mutant cancers ( Fig. 2C ; Table 3 ). Although a substantial percentage (52%, 13 of 25) of p53 mutant cancers that highly express dominant-negative p73 isoforms failed to respond to chemotherapy, only 23.3% (7 of 30) of p53 mutant cancers with low expression levels of dominant-negative p73 isoforms showed chemotherapeutic failure (Fisher's exact test, P = 0.048). Within p53 wild-type cancers, no robust correlation between expression levels of dominant-negative p73 isoforms and response to chemotherapy could be drawn due to small case numbers in these subgroups.
The property of p53 mutations to inhibit TAp73 function did not influence responsiveness to chemotherapy (Table 3) . Of note, patients with residual tumors z2 cm showed the highest rate of TAp73-neutralizing p53 mutations (39.3%, 11 of 28) followed by 21.1% (4 of 19) in patients with residual tumors <2 cm and 12% (3 of 25) in patients with residual tumor 0 (m 2 = 5.5, P = 0.065). p53, p73, and their cross-talk have a significant effect for survival in ovarian cancer. For survival analysis, all FIGO stages were included. In a first step, we determined the relevance of established clinicopathologic variables for recurrence-free and overall survival to validate the reliability of the survival data in our cohort of ovarian cancer patients. As expected, in univariate analysis established variables proved to be significant prognosticators for survival, as summarized in Table 4 . The residual tumor after initial surgery was by far the strongest determinant of recurrence-free and overall survival (P < 0.0001 and P < 0.0001, respectively).
Next, the p53 family members were evaluated for their prognostic value (Table 4 ). The p53 mutational status was a strong prognostic marker for recurrence-free and overall survival in univariate analyses (wild type versus mutant; P < 0.0001 and P = 0.003, respectively; Fig. 3A) . Of interest, patients harboring cancers with TAp73-inhibiting p53 mutations showed significantly worse overall survival (TAp73-inhibiting p53 mutations versus non-TAp73-inhibiting mutations, P = 0.044; Fig. 3B ). Although in patients with p53 mutations that efficiently inhibit TAp73 function, the median survival time was only 36 months, in patients with p53 mutations of unknown effect on TAp73, the median survival was 62 months. No significant difference between these two groups of patients was found for recurrence-free survival. Furthermore, high expression levels of dominantnegative p73 isoforms (DNp73 and DNVp73) correlated unfavorably with recurrence-free and overall survival in p53 mutant cancers (P = 0.048 and P = 0.005, respectively; Fig. 3C) . A median survival of 77 months was seen in patients harboring cancers with low levels of dominant-negative p73 isoforms, as opposed to a median survival of only 20 months in the high expressing group. Again, within p53 wild-type cancers, survival correlations with dominant-negative p73 levels could not be done due to small case numbers in the subgroups.
When data were stratified according to the distinct type of p53 alteration, a strong trend was seen: patients harboring cancers with transitions had a shorter recurrence-free survival than patients with transversions (P = 0.061). This difference reached significance for overall survival (P = 0.028; Fig. 3D ).
For multivariate evaluation of p53 family members as independent prognostic markers, we considered the three strongest clinicopathologic prognosticators from the univariate analysis (residual tumor, FIGO stage, and tumor grading for recurrence-free survival; residual tumor, patients age, and tumor grading for overall survival). Of note, the significance of dominant-negative p73 isoforms in p53 mutant cancers for recurrence-free and overall survival remained in multivariate analysis, even in the presence of other known prognostic markers (P = 0.048 and P = 0.042, respectively). This was not the case for the p53 mutational status (P = 0.149 and P = 0.087, cDue to small numbers, the histologic subtypes clear cell adenocarcinoma (n = 4) and undifferentiated carcinoma (n = 4) have been excluded from statistical analysis. of p53 mutant cancers were poorly differentiated (grade 3). A trend was seen for a higher rate of p53 mutations in advanced FIGO stages (m 2 = 6.9, P = 0.08). Regarding the histologic subtype, 43.2% (32 of 74) p53 mutations were mainly found in serous cancers, whereas 34.8% (25 of 74) occurred in mucinous and 23% (17 of 74) in endometrioid cancers. In contrast, the majority of p53 wild-type cancers were of the mucinous subtype (52.5%, 21 of 40; m 2 = 3.8, P = 0.15). Among the p53 mutations, it was predominantly the missense mutations in highly conserved regions that correlated with the serous histologic subtype (42.4%, 14 of 33), whereas the majority of p53 mutations occurring outside the highly conserved regions were seen in the mucinous subtype (51.7%, 15 of 29; m 2 = 6.8, P = 0.03). When focusing on p53 mutations in functional areas (loop 1, loop 2, loop 3, and loop-sheet-helix motif), this correlation with the serous histologic subtype became even more pronounced (m 2 = 9.4, P = 0.009). Furthermore, transitions in the p53 gene significantly correlated with older age (m 2 = 5.3, P = 0.022). Although 59.6% (28 of 47) transitions were found in patients older than the median age of 61 years, the majority of transversions (69.6%, 16 of 23) were seen in patients V61 years. Particularly, the C>T transition was found in considerably higher frequency in older patients (77.8%, 7 of 9), whereas the G>T and the T>A transversions were predominantly found in younger patients [66.7% (6 of 9) and 75% (3 of 4), respectively].
The codon 72 polymorphism in p53 mutants does not influence clinical response to chemotherapy in ovarian cancer. In vitro data from several laboratories have shown that p53 mutants with an arginine at position 72 (72R) show worse response to chemotherapeutic agents, including cisplatin, than mutants with the 72 proline (72P) variants (4). Thus, we aimed to determine whether this polymorphism at codon 72 also plays a role in response to chemotherapy in vivo in ovarian cancer patients; 53.6% (60 of 112) cases were homozygous for arginine, 36.6% (41 of 112) were heterozygous, and 9.8% (11 of 112) were homozygous for proline. All p53 mutations detected were analyzed for their codon 72 polymorphism; 67.1% (53 of 79) of mutations were on the arginine allele (72R), 30.4% (24 of 79) were on the proline allele (72P), and in two cases (2.5%, 2 of 79), a histidine was found at codon 72. In p53 mutant cancers arising in codon 72 R/P individuals (n = 31), mutations were detected with similar frequency on the arginine (45.2%, 14 of 31, 72R) and on the proline allele (51.6%, 16 of 31, 72P). Of note, no significant difference was found in the rate of chemotherapeutic failure between 72P p53 mutations (8 of 21, 38.1%) and 72R mutations (19 of 49, 38.8%). The two p53 mutant cancers with a histidine at position 72 showed no progression during chemotherapy or early recurrence. In addition, no significant difference in the rate of 72R and 72P mutations was found between TAp73-neutralizing and non-TAp73-neutralizing p53 mutations. Furthermore, there was no significant difference in recurrence-free or overall survival between patients with mutant 72R compared with mutant 72P.
Discussion
Prompted by a series of detailed in vitro studies on the p53-p73 network and its importance in mediating cytotoxicity of chemotherapeutic drugs, this study examines the clinical relevance of these findings. We herein present the first clinical Fig. 2 . Factors that determine responsiveness to first-line platinum-based chemotherapy. Chemotherapeutic failure is defined as primary progression during chemotherapy or early recurrence within 6 months after termination of chemotherapy and is compared with a recurrence-free survival of >12 months. A, residual tumor after initial surgery is a crucial determinant of responsiveness to chemotherapy. B, in the subgroup of patients with residual tumors <2 cm, responsiveness to chemotherapy significantly correlates with p53 mutational status. C, expression level of dominant-negative p73 isoforms (DNp73 and DNV p73) in p53 mutant cancers. study combining a complete p53 mutational analysis, including codon 72 polymorphism, quantitative isoform-specific p73 expression, and clinical data on chemoresponsiveness and survival. This allows us to address several crucial clinical questions that await resolution.
First, we wanted to determine whether NH 2 -terminally truncated, dominant-negative p73 isoforms contribute to chemotherapeutic failure in vivo. In vitro experiments clearly showed that NH 2 -terminally truncated p73 isoforms act as dominant-negative inhibitors of TAp73, thereby inhibiting drug-induced, TAp73-depending apoptosis (4, 5) . To date, definitive evidence for a clinical role of NH 2 -terminally truncated p73 isoforms in mediating drug resistance is lacking. Of note, our data indicate that dominant-negative p73 isoforms (DNp73 and DNVp73) are important determinants for failure to platinum-based chemotherapy in p53 mutant <0.001 ovarian cancers. In view of the in vitro experiments, these data are consistent with the notion that dominant-negative p73 isoforms promote chemotherapeutic failure through inhibition of the alternative TAp73-mediated apoptotic pathway in p53 mutant ovarian cancer. This hypothesis would further implicate a critical in vivo role of TAp73 in the response to chemotherapy. Besides inhibition of TAp73 function, other currently unknown mechanisms might be active through which dominant-negative p73 isoforms promote failure to chemotherapy. Our study could not prove an influence of dominantnegative p73 isoforms on clinical chemoresponsiveness in p53 wild-type cancers. In vitro data clearly implicate dominantnegative p73 isoforms as potent inhibitors of the proapoptotic TAp73 and wild-type p53 functions (4, 7) . This suggests that high expression levels of dominant-negative p73 isoforms in p53 wild-type cancers are unfavorable for responsiveness to chemotherapy. In addition, we previously found dominant-negative p73 isoforms to be expressed at a significantly higher level in p53 wild-type compared with p53 mutant ovarian cancers (6) . However, from our clinical study, the possibility arises that dominant-negative p73 isoforms might have a minor in vivo relevance regarding chemoresponsiveness in p53 wild-type cancers. Caution has to be applied when interpreting our findings in p53 wild-type tumors because the small case numbers do not allow us to draw reliable conclusions. Further studies, including a large number of p53 wild-type cancers, are needed to clarify the in vivo role of dominant-negative p73 isoforms in responsiveness to chemotherapy.
In view of the in vitro data, we also determined whether the property of the specific p53 mutation to inhibit TAp73 function is of clinical importance in ovarian cancers. However, in our cohort of ovarian cancers, the capacity of p53 mutations to neutralize TAp73 had no influence on responsiveness to chemotherapy. This finding is in contrast to the study of Bergamaschi et al., who examined a series of 70 inoperable head and neck cancers treated with chemoradiotherapy and reported a significant higher rate of chemoresistance in p53 mutant cancers that neutralize TAp73 compared with cancers with non-TAp73-neutralizing p53 mutations (4) . Of note, several p53 mutations found in our cohort of ovarian cancers have been analyzed for their interaction with p73. Thus, we cannot exclude that p73-neutralizing p53 mutations are hidden in this group and bias our results. Nevertheless, from our data, we conclude that in p53 mutant ovarian cancers, the expression of dominantnegative isoforms is of stronger influence on responsiveness to chemotherapy than the property of the specific p53 mutation to inhibit TAp73 function.
Furthermore, we addressed the question whether dominantnegative p73 is a prognostic marker for survival. Here, our data on chemotherapy response are reflected in the survival analysis. With the updated and completed survival data, we now show that high expression levels of dominant-negative p73 isoforms are an unfavorable prognostic marker for recurrence-free and overall survival in p53 mutant cancers. Previously, based on a subset of the current ovarian cancer cohort with shorter follow-up, we found a strong but not significant trend towards worse survival in patients with high expression levels of dominant-negative p73 isoforms (6) . Studies in human cancers, discriminating between TAp73 and its NH 2 -terminally truncated isoforms with opposing function, remain uncommon and even when analyzed often disregard the functional interactions with p53/p73 (19, 20) . In neuroblastomas and lung cancer, expression of dominantnegative p73 was correlated with poor survival, although both studies did not analyze p53 mutational status. Further clinical studies combining a full analysis of p53 and p73 isoforms are therefore necessary to better understand the in vivo relevance of p73 and its interaction with p53. Indeed, the strongest endorsement for a tumor-promoting role of any candidate human oncogene, such as NH 2 -terminally truncated p73 isoforms, is a direct effect on survival. Interestingly, although not relevant for responsiveness to chemotherapy and therefore for recurrence-free survival, the property of p53 mutations to inhibit TAp73 function was of significant influence on overall survival.
In p53 mutant cancers, the proapoptotic TAp73 can be inactivated by specific p53 mutants and DNp73 proteins. In addition, a remaining wild-type p53 protein from a second allele can also be inactivated by mutant p53 and dominantnegative p73. Thus, the question arises whether DNp73 protein is functionally redundant in p53 mutant cancers. Our data on responsiveness to chemotherapy and survival strongly argue that dominant-negative p73 is not functionally redundant in p53 mutant cancers but provides an additional unfavorable factor.
In the examined cohort of ovarian cancers, the p53 mutational status itself (wild type versus mutant) was a strong predictive determinant for response to chemotherapy in satisfactorily debulked patients (<2 cm). Of interest, in patients who were left with residual tumor z2 cm after surgery, p53 mutational status was not crucial for responsiveness to chemotherapy. We hypothesize that these tumors might differ in their inherent biology from the ones that could be debulked satisfactorily. Debulking efficiency might not solely depend on the skills of the surgeon but might be influenced by the intrinsic aggressiveness of the tumor (21) . This hypothesis is in line with the finding that the smallest incidence of p53 wild-type tumors (only 7 of 33 cases) and the highest incidence of TAp73-inhibiting p53 mutations were found in patients with residual tumor z2 cm. The independence of chemoresponsiveness from p53 mutational status in patients with residual tumor 0 can probably be explained by the high number of FIGO stage I patients in this group. In these early stages, chemotherapy is less important compared with advanced disease. Although the whole tumor can surgically be removed in patients with FIGO stage I, patients with advanced disease present with peritoneal carcinomatosis where surgery alone is insufficient.
p53 was also a prognostic marker for recurrence-free and overall survival in univariate analyses. Contradictory data in the literature on the relevance of p53 mutational status in ovarian cancer might be explained in part by less sensitive methods used to determine p53 mutations, such as immunohistochemistry or direct sequencing from normal tissue-contaminated samples. This point is underscored by the higher percentage of p53 mutations in our ovarian cancer cohort compared with other studies that report rates between 46% and 56% (22 -25) . Of note, in addition to a large number of advanced ovarian cancers, our study also included 37 cases of FIGO stage I and II cancers.
An interesting aspect of our data was the crucial influence of the distinct type of a p53 alteration (i.e., transversion or transition) on survival. From a multivariate analysis, we can conclude that this influence is probably due the strong correlation of transitions/transversions with patient age, a well-established prognostic marker in ovarian cancer. In concordance with our data, a recent study of Wang et al. also showed a clear correlation of the distinct type of p53 alteration with patient age in ovarian cancer (26) . However, the question remains why transitions rather than transversions preferentially occur in elderly patients. Environmental and genetic factors have been linked to distinct nucleotide changes in the p53 gene, such as tobacco smoke and alcohol in the case of G>T transversions (27) or in breast cancer patients carrying the BRCA1/2 germ line variant to A>T transitions (28) . Thus, we speculate that the different distribution of transition versus transversion might reflect variable genetic or environmental factors influencing carcinogenesis in the two age groups.
An arginine/proline polymorphism at codon 72 of p53 has been described to influence the ability of specific p53 missense mutants in the DNA-binding domain to inhibit the TAp73 function (29) . In a recent study, Bergamaschi et al. examined a large panel of tumor-derived p53 mutants in vitro and found that the 72R variants of specific p53 mutants more efficiently inhibited cisplatin-induced, p73-dependent apoptosis compared with the corresponding 72P variants (4) . In a first clinical study in head and neck tumors, these authors found their in vitro data reflected in vivo, showing a significant better response to chemoradiotherapy in patients with 72P p53 mutants rather than with 72R mutants. However, we could not confirm a clinical relevance regarding responsiveness to chemotherapy or survival for 72P p53 mutants versus 72R mutants in ovarian cancers.
When interpreting our results, the limitations of this study have to be considered. Several subgroup analyses regarding the clinical effect of the examined p53 family members were done, and no corrections for multiple comparisons were applied due to the explorative character of these analyses. Some of our findings arose from subgroup analyses with relatively small case numbers. From analyses in p53 wild-type cancers, no reliable conclusions can be drawn due to small case numbers. Another drawback of this study is that in addition to the p53 mutations that are known to efficiently inhibit TAp73 function, our cohort harbored a large amount of p53 mutations of unknown interaction with TAp73. This can clearly bias our results. Indeed, confirmatory clinical studies are needed.
Taken together, we provide the first evidence that dominantnegative p73 isoforms contribute to drug resistance in vivo. NH 2 -terminally truncated p73 isoforms were of significant clinical effect by providing an additional unfavorable factor for response to chemotherapy and survival in p53 mutant ovarian cancers.
